The Medical Briefing Nephrology
Ravulizumab in IgA nephropathy, dual diuretic therapy, fish oil in hemodialysis, CAR-T and fibrosis
Retrospective no. 5/12
The essentials in four articles
■ Glomerular disease
Phase III interim analysis (352 patients): urine protein/creatinine ratio −46.6% with ravulizumab vs −5.6% with placebo at 34 weeks; hematuria resolution 42.4% vs 11.1%. Interim endpoints, GFR data not available.
■ AKI and critical care
Post-hoc analysis of CLOROTIC (225 patients): adding hydrochlorothiazide to the loop diuretic accentuates the early GFR fall (−14.4% at day 4 vs 0%), with no association with mortality or rehospitalization at 3 months.
■ CKD and dialysis
Editorial on PISCES: 4 g/day of omega-3 in 1,228 hemodialysis patients, severe cardiovascular events reduced by 43%. Antiarrhythmic effect hypothesized; a single trial is not enough to conclude.
■ CKD and dialysis
PDGFRβ+ fibroblasts produce CKD fibrosis; their selective elimination protects kidney function in mice. CAR-T cells could target these cells: an antifibrotic lead, so far based on a mouse model.